Lumos Pharma Stock Forecast for 2023 - 2025 - 2030

Updated on 05/21/2024

Stock Rating
-11
Price Target
$23.00
Consensus
Outperform
Upside
777.86%
Analysts
2
Stock Rating
-11
Upside
777.86%
Analysts
2
Price Target
$23.00

Lumos Pharma Stock Forecast and Price Target

Lumos Pharma's stock is projected to advance by 777.86% from the previous closing price if it reaches the average target of $23.00 by the year's end, as two reputable analysts recently projected. This potential upside is calculated on a high-end estimate of $28.00 and a low-end estimate of $16.00.

$23.00

777.86% Upside

Buy
Buy

Lumos Pharma Fair Value Forecast for 2023 - 2025 - 2030

In the last four years, Lumos Pharma's Price has grown from $0.00 to $0.00 – a 100.00% increase. Next year, analysts are expecting Fair Value to reach $2.80 – an increase of 100.00%. Over the next seven years, the forecast is for Fair Value to grow by 100.00%.

2024 Fair Value Forecast
$2.80
2025 Fair Value Forecast
$3.11
2026 Fair Value Forecast
$3.46
2027 Fair Value Forecast
$3.85
2028 Fair Value Forecast
$4.28
2029 Fair Value Forecast
$4.76
2030 Fair Value Forecast
$5.29

Lumos Pharma Revenue Forecast for 2023 - 2025 - 2030

In the last three years, Lumos Pharma's Revenue has grown from $170.00k to $2.05M – a 1105.88% increase. According to 4 prominent analysts, Lumos Pharma's Revenue will fall by 80.00% in the next year, reaching $410.00k. Over the next seven years, the forecast is for Revenue to grow by 27234.15%.

2024 Rev Forecast
$410.00k
2025 Rev Forecast
$0.01B
2026 Rev Forecast
$0.06B
2027 Rev Forecast
$0.12B
2028 Rev Forecast
$0.32B
2029 Rev Forecast
$0.43B
2030 Rev Forecast
$0.56B

Lumos Pharma Dividend per Share Forecast for 2023 - 2025 - 2030

Lumos Pharma Free Cash Flow Forecast for 2023 - 2025 - 2030

2024 FCF Forecast
$-41870000.00
2025 FCF Forecast
$-44610000.00
2026 FCF Forecast
$-40310000.00
2027 FCF Forecast
$-34050000.00
2028 FCF Forecast
$-18630000.00
2029 FCF Forecast
$0.01B
2030 FCF Forecast
$0.09B

Lumos Pharma EBITDA Forecast for 2023 - 2025 - 2030

In the last three years, Lumos Pharma's EBITDA has grown, rising from $-25.72M to $-36.57M – a growth of 42.19%. In the next year, 0 analysts estimate that Lumos Pharma's EBITDA will decrease by 10.87%, reaching $-32.59M. According to professional forecasts, in 2030, Lumos Pharma's EBITDA will decrease by 10.37%, reaching $-32.78M.

2024 EBITDA Forecast
$-32593622.00
2025 EBITDA Forecast
$-32245956.70
2026 EBITDA Forecast
$-32327646.46
2027 EBITDA Forecast
$-33731743.90
2028 EBITDA Forecast
$-33357321.54
2029 EBITDA Forecast
$-32991502.92
2030 EBITDA Forecast
$-32779257.58

Lumos Pharma EBIT Forecast for 2023 - 2025 - 2030

Lumos Pharma's EBIT has grown In the last three years, rising from $-26.30M to $-36.61M – a growth of 39.20%. In the next year, analysts believe that EBIT will reach $-46.65M – an increase of 27.42%. Professionals believe that By 2030, Lumos Pharma's EBIT will fall to $401.27M – a 1196.07% decrease from its current value.

2024 EBIT Forecast
$-46650000.00
2025 EBIT Forecast
$-40030000.00
2026 EBIT Forecast
$-5800000.00
2027 EBIT Forecast
$0.04B
2028 EBIT Forecast
$0.20B
2029 EBIT Forecast
$0.29B
2030 EBIT Forecast
$0.40B

Lumos Pharma EPS Price Prediction Forecast for 2023 - 2025 - 2030

In the last four years, Lumos Pharma's EPS has grown from $-0.93 to $0.00 – a 100.00% increase. Next year, analysts are expecting EPS to reach $-3.94 – an increase of 100.00%. Over the next seven years, the forecast is for EPS to grow by 100.00%.

2024 EPS Forecast
$-3.94
2025 EPS Forecast
$-2.69
2026 EPS Forecast
$1.75
2027 EPS Forecast
$7.41
2028 EPS Forecast
$14.26
2029 EPS Forecast
$14.84
2030 EPS Forecast
$20.27